Drug Profile
Research programme: heparosan-based conjugates - Caisson Biotech/Novo Nordisk
Latest Information Update: 26 Feb 2021
Price :
$50
*
At a glance
- Originator Caisson Biotech; Novo Nordisk
- Class Amino sugars; Drug conjugates; Glucuronic acids; Insulins; Pancreatic hormones; Polysaccharides
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetes mellitus; Haemophilia
Most Recent Events
- 23 Feb 2021 Caisson Biotech and Heparinex receives a positive report from the European Patent Office for chemoenzymatic production of heparosan used in the HEPtune® drug delivery platform in Europe.
- 28 Jul 2018 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA
- 28 Jul 2018 No recent reports of development identified for research development in Haemophilia in USA